Olema Oncology, Inc. (OLMA) stock
OLMANasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.36−0.20 (-2.65%)
Close on Nov 16, 2026Market cap $643.98MP/E –Yield –
Olema Oncology r&d expenses
Research and development expenses are spending on new products and technology.
Olema Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $190.19M, up 35.8% year over year. For fiscal 2025 it was $157.70M, up 26.6% from the year before. The highest annual figure on record is $157.70M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $157.70M | +26.6% |
| FY2024 | Dec 31, 2024 | $124.52M | +44.6% |
| FY2023 | Dec 31, 2023 | $86.14M | +4.7% |
| FY2022 | Dec 31, 2022 | $82.27M | +61.0% |
| FY2021 | Dec 31, 2021 | $51.10M | +272.9% |
| FY2020 | Dec 31, 2020 | $13.70M | +249.6% |
| FY2019 | Dec 31, 2019 | $3.92M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $57.79M | +31.6% |
| Q1 FY2026 | Mar 31, 2026 | $49.23M | +60.8% |
| Q4 FY2025 | Dec 31, 2025 | $43.22M | +33.8% |
| Q3 FY2025 | Sep 30, 2025 | $39.95M | +20.2% |
| Q2 FY2025 | Jun 30, 2025 | $43.90M | +50.8% |
| Q1 FY2025 | Mar 31, 2025 | $30.62M | +2.5% |
| Q4 FY2024 | Dec 31, 2024 | $32.30M | +24.8% |
| Q3 FY2024 | Sep 30, 2024 | $33.23M | +70.8% |
| Q2 FY2024 | Jun 30, 2024 | $29.11M | +61.8% |
| Q1 FY2024 | Mar 31, 2024 | $29.88M | +30.9% |
| Q4 FY2023 | Dec 31, 2023 | $25.87M | +19.9% |
| Q3 FY2023 | Sep 30, 2023 | $19.45M | +10.4% |
| Q2 FY2023 | Jun 30, 2023 | $17.99M | -33.5% |
| Q1 FY2023 | Mar 31, 2023 | $22.83M | +42.6% |
| Q4 FY2022 | Dec 31, 2022 | $21.58M | +35.1% |
| Q3 FY2022 | Sep 30, 2022 | $17.63M | +40.8% |
| Q2 FY2022 | Jun 30, 2022 | $27.05M | +127.2% |
| Q1 FY2022 | Mar 31, 2022 | $16.01M | +49.7% |
| Q4 FY2021 | Dec 31, 2021 | $15.98M | +154.0% |
| Q3 FY2021 | Sep 30, 2021 | $12.52M | +168.0% |
| Q2 FY2021 | Jun 30, 2021 | $11.91M | +511.7% |
| Q1 FY2021 | Mar 31, 2021 | $10.69M | +1244.9% |
| Q4 FY2020 | Dec 31, 2020 | $6.29M | – |
| Q3 FY2020 | Sep 30, 2020 | $4.67M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.95M | – |
| Q1 FY2020 | Mar 31, 2020 | $795.00K | – |
See a number that looks wrong?